| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 17 | 2025 | 148 | 2.550 |
Why?
|
| Ubiquitin Thiolesterase | 9 | 2025 | 55 | 1.590 |
Why?
|
| Tumor Suppressor Proteins | 11 | 2025 | 222 | 1.530 |
Why?
|
| Lung Neoplasms | 9 | 2025 | 479 | 1.070 |
Why?
|
| Brain Neoplasms | 10 | 2017 | 129 | 1.000 |
Why?
|
| HMGB1 Protein | 5 | 2023 | 30 | 0.800 |
Why?
|
| Asbestos | 6 | 2024 | 57 | 0.740 |
Why?
|
| Pleural Neoplasms | 3 | 2016 | 57 | 0.720 |
Why?
|
| Germ-Line Mutation | 6 | 2025 | 74 | 0.720 |
Why?
|
| Glioblastoma | 8 | 2017 | 69 | 0.690 |
Why?
|
| Glioma | 5 | 2015 | 92 | 0.540 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 130 | 0.530 |
Why?
|
| Cell Nucleus | 4 | 2021 | 383 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 727 | 0.420 |
Why?
|
| Mutation | 7 | 2023 | 1169 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2020 | 165 | 0.360 |
Why?
|
| Phosphoproteins | 2 | 2010 | 201 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 209 | 0.330 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 66 | 0.320 |
Why?
|
| Mice | 26 | 2023 | 6490 | 0.320 |
Why?
|
| Melanoma | 2 | 2022 | 109 | 0.280 |
Why?
|
| Molecular Biology | 1 | 2008 | 47 | 0.270 |
Why?
|
| Animals | 29 | 2023 | 16695 | 0.240 |
Why?
|
| Calcium Signaling | 2 | 2024 | 108 | 0.240 |
Why?
|
| Heterozygote | 5 | 2025 | 107 | 0.230 |
Why?
|
| Picolinic Acids | 6 | 2006 | 12 | 0.220 |
Why?
|
| Humans | 37 | 2025 | 42163 | 0.220 |
Why?
|
| Mitochondria | 3 | 2017 | 516 | 0.220 |
Why?
|
| Signal Transduction | 5 | 2017 | 2111 | 0.220 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2023 | 85 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 90 | 0.200 |
Why?
|
| Antineoplastic Agents | 6 | 2017 | 979 | 0.200 |
Why?
|
| DNA Repair | 1 | 2024 | 196 | 0.200 |
Why?
|
| Histone Deacetylase 1 | 1 | 2021 | 16 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 62 | 0.180 |
Why?
|
| Epithelial Cells | 3 | 2020 | 426 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2017 | 933 | 0.180 |
Why?
|
| Apoptosis | 7 | 2024 | 1541 | 0.180 |
Why?
|
| Autophagy | 2 | 2020 | 136 | 0.180 |
Why?
|
| Asbestosis | 1 | 2020 | 7 | 0.170 |
Why?
|
| RecQ Helicases | 1 | 2020 | 35 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2017 | 339 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 175 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 8 | 2017 | 506 | 0.160 |
Why?
|
| Cell Hypoxia | 5 | 2011 | 57 | 0.160 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 928 | 0.160 |
Why?
|
| Prognosis | 5 | 2025 | 850 | 0.160 |
Why?
|
| Cell Line, Tumor | 11 | 2017 | 2598 | 0.150 |
Why?
|
| Biopsy | 2 | 2016 | 176 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 98 | 0.150 |
Why?
|
| Cell Survival | 7 | 2017 | 934 | 0.140 |
Why?
|
| Macrophages | 5 | 2006 | 515 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 602 | 0.140 |
Why?
|
| Cell Proliferation | 6 | 2017 | 1420 | 0.140 |
Why?
|
| Endothelial Cells | 3 | 2011 | 324 | 0.140 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 10 | 0.130 |
Why?
|
| Mice, Knockout | 4 | 2020 | 1010 | 0.130 |
Why?
|
| Pyruvates | 1 | 2017 | 6 | 0.130 |
Why?
|
| Stem Cell Factor | 2 | 2008 | 7 | 0.130 |
Why?
|
| Guanidines | 1 | 2017 | 18 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 15 | 0.130 |
Why?
|
| Cytoplasm | 1 | 2017 | 154 | 0.130 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 92 | 0.130 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 108 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 53 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 88 | 0.130 |
Why?
|
| Magnesium Compounds | 1 | 2016 | 2 | 0.120 |
Why?
|
| Silicon Compounds | 1 | 2016 | 7 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 236 | 0.120 |
Why?
|
| Uveal Neoplasms | 1 | 2015 | 11 | 0.120 |
Why?
|
| Macrophage Activation | 4 | 2004 | 59 | 0.120 |
Why?
|
| Drug Design | 1 | 2017 | 183 | 0.120 |
Why?
|
| Mice, SCID | 5 | 2017 | 158 | 0.110 |
Why?
|
| Glutamine | 1 | 2015 | 36 | 0.110 |
Why?
|
| Protein Binding | 5 | 2021 | 1076 | 0.110 |
Why?
|
| Interferon-gamma | 4 | 2004 | 268 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 382 | 0.110 |
Why?
|
| Calcium | 1 | 2017 | 487 | 0.110 |
Why?
|
| Down-Regulation | 5 | 2014 | 452 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 112 | 0.110 |
Why?
|
| Drug Approval | 1 | 2014 | 10 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 28 | 0.110 |
Why?
|
| Staurosporine | 1 | 2013 | 38 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 147 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 38 | 0.100 |
Why?
|
| Nanocapsules | 1 | 2013 | 19 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2016 | 247 | 0.100 |
Why?
|
| Piperidines | 2 | 2004 | 80 | 0.100 |
Why?
|
| Female | 12 | 2025 | 24018 | 0.100 |
Why?
|
| Middle Aged | 7 | 2025 | 11819 | 0.100 |
Why?
|
| Flavonoids | 2 | 2004 | 94 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2013 | 124 | 0.100 |
Why?
|
| Liposomes | 1 | 2013 | 130 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 318 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 5 | 2010 | 1804 | 0.100 |
Why?
|
| Genomic Instability | 2 | 2024 | 36 | 0.100 |
Why?
|
| Neuroblastoma | 2 | 2004 | 134 | 0.100 |
Why?
|
| Inflammation | 3 | 2023 | 729 | 0.100 |
Why?
|
| Aged | 6 | 2025 | 7982 | 0.090 |
Why?
|
| Mice, Nude | 4 | 2017 | 403 | 0.090 |
Why?
|
| Incidence | 3 | 2021 | 1054 | 0.090 |
Why?
|
| Male | 9 | 2025 | 22779 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 160 | 0.090 |
Why?
|
| Pedigree | 2 | 2025 | 94 | 0.090 |
Why?
|
| Cell Transdifferentiation | 1 | 2011 | 8 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 62 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 94 | 0.080 |
Why?
|
| Jurkat Cells | 1 | 2010 | 84 | 0.080 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 60 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2020 | 1617 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2010 | 90 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 287 | 0.080 |
Why?
|
| Fibroblasts | 2 | 2024 | 278 | 0.080 |
Why?
|
| Ubiquitin | 2 | 2021 | 80 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 29 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 18 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 18 | 0.070 |
Why?
|
| Cell Line | 5 | 2015 | 1416 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 686 | 0.070 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2007 | 20 | 0.070 |
Why?
|
| Nitrosourea Compounds | 1 | 2007 | 1 | 0.070 |
Why?
|
| Stathmin | 1 | 2007 | 2 | 0.070 |
Why?
|
| Oligodendroglioma | 1 | 2007 | 6 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 12 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 378 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 47 | 0.070 |
Why?
|
| Uterus | 1 | 2007 | 57 | 0.070 |
Why?
|
| Moloney murine leukemia virus | 1 | 2006 | 7 | 0.070 |
Why?
|
| Adult | 5 | 2025 | 13458 | 0.060 |
Why?
|
| Glucose | 1 | 2008 | 242 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 201 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2017 | 50 | 0.060 |
Why?
|
| Macrophage Inflammatory Proteins | 2 | 2003 | 16 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 69 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 44 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 501 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2016 | 1265 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 189 | 0.060 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2006 | 115 | 0.060 |
Why?
|
| Phenotype | 2 | 2025 | 774 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2008 | 196 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2008 | 355 | 0.060 |
Why?
|
| Genes, myc | 1 | 2004 | 30 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 29 | 0.060 |
Why?
|
| Alleles | 2 | 2016 | 352 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 290 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 146 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 127 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2007 | 633 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 1554 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 404 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2015 | 84 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 95 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 9 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2017 | 43 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 17 | 0.050 |
Why?
|
| Tryptophan | 1 | 2003 | 66 | 0.050 |
Why?
|
| Spheroids, Cellular | 2 | 2014 | 37 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2011 | 973 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 233 | 0.050 |
Why?
|
| Genome, Human | 2 | 2016 | 143 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 310 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1058 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 548 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 379 | 0.040 |
Why?
|
| Fungi | 1 | 2002 | 103 | 0.040 |
Why?
|
| Asbestos, Crocidolite | 1 | 2020 | 8 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 1066 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2005 | 722 | 0.040 |
Why?
|
| RNA, Small Interfering | 3 | 2008 | 436 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 89 | 0.040 |
Why?
|
| RNA Interference | 2 | 2015 | 246 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 98 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2013 | 206 | 0.040 |
Why?
|
| Family | 1 | 2020 | 192 | 0.040 |
Why?
|
| Neurons | 1 | 2006 | 1246 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 2803 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 1452 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 47 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 2017 | 25 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 599 | 0.030 |
Why?
|
| Epithelium | 1 | 2017 | 78 | 0.030 |
Why?
|
| Transcription, Genetic | 3 | 2006 | 599 | 0.030 |
Why?
|
| Germ Cells | 1 | 2017 | 74 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 37 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 60 | 0.030 |
Why?
|
| Multigene Family | 1 | 2016 | 105 | 0.030 |
Why?
|
| Caspases | 2 | 2008 | 148 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 180 | 0.030 |
Why?
|
| Nevada | 1 | 2016 | 5 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2016 | 8 | 0.030 |
Why?
|
| Genealogy and Heraldry | 1 | 2015 | 5 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 185 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 24 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 366 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 154 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2017 | 420 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 108 | 0.030 |
Why?
|
| Osteopontin | 1 | 2016 | 45 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 78 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2007 | 462 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 8 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 560 | 0.030 |
Why?
|
| New York | 1 | 2015 | 88 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 358 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 181 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 4936 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2015 | 181 | 0.030 |
Why?
|
| Camptothecin | 1 | 2014 | 24 | 0.030 |
Why?
|
| United States | 2 | 2015 | 5072 | 0.030 |
Why?
|
| Diffusion | 1 | 2013 | 63 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 116 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 144 | 0.030 |
Why?
|
| Deferoxamine | 2 | 2004 | 17 | 0.030 |
Why?
|
| Quinolines | 1 | 2014 | 76 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 649 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 189 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 640 | 0.030 |
Why?
|
| Chemokine CCL3 | 2 | 2003 | 14 | 0.020 |
Why?
|
| Chemokine CCL4 | 2 | 2003 | 19 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2014 | 167 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 64 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 37 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 91 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2011 | 19 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 168 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 2011 | 22 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1112 | 0.020 |
Why?
|
| Brain Edema | 1 | 2011 | 64 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2011 | 61 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 159 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 137 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 301 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1586 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 12 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 111 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 860 | 0.020 |
Why?
|
| COS Cells | 1 | 2007 | 67 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 80 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2008 | 79 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 233 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2008 | 107 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 217 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2485 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 207 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 25 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 314 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 78 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 57 | 0.020 |
Why?
|
| Terminal Repeat Sequences | 1 | 2006 | 8 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 456 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 198 | 0.020 |
Why?
|
| Hela Cells | 1 | 2007 | 370 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 295 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 19 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 14 | 0.020 |
Why?
|
| Serum | 1 | 2006 | 17 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2006 | 165 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 884 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2006 | 36 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2005 | 15 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 658 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 997 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 353 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 25 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2004 | 36 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 129 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 25 | 0.010 |
Why?
|
| G2 Phase | 1 | 2004 | 29 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 48 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 33 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 138 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2005 | 80 | 0.010 |
Why?
|
| Thiazoles | 1 | 2004 | 76 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 100 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1559 | 0.010 |
Why?
|
| RNA Stability | 1 | 2004 | 28 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 534 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 387 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 796 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 2002 | 3 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 39 | 0.010 |
Why?
|
| Half-Life | 1 | 2002 | 63 | 0.010 |
Why?
|
| Macrophages, Peritoneal | 1 | 2002 | 23 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 96 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 217 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 75 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 711 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 10 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 457 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 235 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 2002 | 21 | 0.010 |
Why?
|
| Ferrous Compounds | 1 | 2002 | 23 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 683 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1188 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2002 | 86 | 0.010 |
Why?
|
| Mycoses | 1 | 2002 | 31 | 0.010 |
Why?
|
| Protein Engineering | 1 | 2002 | 47 | 0.010 |
Why?
|
| Chemokines | 1 | 2003 | 97 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 764 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 134 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 1737 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 2002 | 62 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 594 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 522 | 0.010 |
Why?
|
| Candida albicans | 1 | 2002 | 173 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2002 | 169 | 0.010 |
Why?
|
| Microglia | 1 | 2002 | 204 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 692 | 0.010 |
Why?
|